Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
ParonychiaEGFR-TKIALK-TKI
Interventions
DRUG

Timolol 0.5% eye drops and betamethasone valerate 0.1% cream

Topical timolol 0.5% eye drops (liquid form) twice daily with occlusion (i.e. covered with adhesive badge) and betamethasone valerate 0.1% cream twice daily with occlsuion for 1 month. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.

DRUG

Betamethasone valerate 0.1% cream

The management according to routine clinical practice, including prescription of betamethasone valerate 0.1% cream twice daily for 1 month with occlusion. For patients who do not have paronychia completely resolved after 4 weeks, the treatment assigned will be continued for another 4 to 8 weeks, up to 12 weeks to see the effect.

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Queen Mary Hospital, Hong Kong

OTHER